Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 3 | 2021 | 43 | 1.440 |
Why?
|
| Oncologists | 2 | 2021 | 32 | 1.280 |
Why?
|
| Intestinal Obstruction | 2 | 2021 | 86 | 1.160 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2024 | 269 | 0.990 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 420 | 0.960 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2021 | 17 | 0.650 |
Why?
|
| Surgical Procedures, Operative | 1 | 2022 | 225 | 0.620 |
Why?
|
| Informed Consent | 1 | 2022 | 351 | 0.610 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 100 | 0.540 |
Why?
|
| Cesarean Section | 2 | 2025 | 426 | 0.530 |
Why?
|
| Cancer Survivors | 2 | 2018 | 283 | 0.500 |
Why?
|
| Hemoperitoneum | 1 | 2015 | 9 | 0.460 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 421 | 0.440 |
Why?
|
| Postoperative Hemorrhage | 1 | 2015 | 83 | 0.430 |
Why?
|
| Papillomavirus Infections | 2 | 2024 | 394 | 0.420 |
Why?
|
| Phlebotomy | 1 | 2012 | 20 | 0.370 |
Why?
|
| Developed Countries | 1 | 2012 | 43 | 0.370 |
Why?
|
| Placenta Accreta | 2 | 2025 | 182 | 0.360 |
Why?
|
| Palliative Care | 3 | 2021 | 443 | 0.360 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 33 | 0.360 |
Why?
|
| Ultrasonography | 1 | 2015 | 943 | 0.330 |
Why?
|
| Developing Countries | 1 | 2012 | 305 | 0.310 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2018 | 50 | 0.270 |
Why?
|
| Balloon Occlusion | 1 | 2025 | 48 | 0.220 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 57 | 0.220 |
Why?
|
| Blood Loss, Surgical | 1 | 2025 | 168 | 0.200 |
Why?
|
| Specimen Handling | 1 | 2024 | 146 | 0.200 |
Why?
|
| Female | 13 | 2025 | 70963 | 0.190 |
Why?
|
| Hysterectomy | 1 | 2025 | 202 | 0.190 |
Why?
|
| Self Care | 1 | 2024 | 231 | 0.190 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 123 | 0.180 |
Why?
|
| Herpesviridae Infections | 1 | 2023 | 148 | 0.170 |
Why?
|
| Humans | 16 | 2025 | 131163 | 0.170 |
Why?
|
| Chicago | 1 | 2020 | 22 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 512 | 0.150 |
Why?
|
| Social Environment | 1 | 2018 | 113 | 0.130 |
Why?
|
| Pain | 1 | 2021 | 450 | 0.130 |
Why?
|
| Violence | 1 | 2018 | 129 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 441 | 0.130 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 41 | 0.130 |
Why?
|
| Communication | 1 | 2021 | 543 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 274 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1224 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 889 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2020 | 564 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1272 | 0.110 |
Why?
|
| Adult | 6 | 2025 | 31282 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 398 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1586 | 0.100 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2012 | 7 | 0.090 |
Why?
|
| Acetic Acid | 1 | 2012 | 17 | 0.090 |
Why?
|
| Hyperbilirubinemia | 1 | 2012 | 43 | 0.090 |
Why?
|
| Pregnancy | 3 | 2025 | 7512 | 0.090 |
Why?
|
| Vaginal Smears | 1 | 2012 | 48 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2015 | 824 | 0.090 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 61 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 712 | 0.090 |
Why?
|
| Bilirubin | 1 | 2012 | 126 | 0.090 |
Why?
|
| Triage | 1 | 2012 | 144 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 1826 | 0.080 |
Why?
|
| Papillomavirus Vaccines | 1 | 2012 | 113 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2025 | 17753 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6797 | 0.080 |
Why?
|
| Middle Aged | 5 | 2024 | 28601 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 555 | 0.080 |
Why?
|
| Neoplasms | 1 | 2023 | 3016 | 0.070 |
Why?
|
| Aged | 3 | 2021 | 21025 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5196 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2015 | 6459 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2024 | 97 | 0.050 |
Why?
|
| Operative Time | 1 | 2025 | 201 | 0.050 |
Why?
|
| Postpartum Hemorrhage | 1 | 2025 | 111 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12936 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2025 | 294 | 0.050 |
Why?
|
| Prenatal Diagnosis | 1 | 2025 | 612 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2021 | 124 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1445 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2049 | 0.040 |
Why?
|
| Neutropenia | 1 | 2021 | 209 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 223 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 775 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2012 | 8635 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 386 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 46 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2025 | 3359 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2021 | 388 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3686 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 915 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1106 | 0.030 |
Why?
|
| Male | 1 | 2015 | 64957 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 6099 | 0.020 |
Why?
|